Thalassemia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
No edit summary
Line 7: Line 7:


==Differential Diagnosis==
==Differential Diagnosis==
{| class="wikitable"
!Characteristic/Parameter
!Etiology
!Mean corpuscular volume
!Laboratory abnormalities
!Physical examination
!Treatment
!Other associated abnormalities
|-
|Hemolytic anemia
|
* [[Drug-induced]]
* [[Immune-mediated disease|Immune-mediated]]
* Non-immune-mediated
* [[Infections]]
* [[Rheumatologic disease]]
|
* [[Normocytic anemia|Normocytic]] (80-100 femtoliter)
|
* Indirect [[hyperbilirubinemia]]
* [[Reticulocytosis]]
* Low [[haptoglobin]]
* Elevated [[LDH]]
|
* [[Pallor]]
* [[Jaundice]]
|
* Removal of offending agent
* [[Steroids]]
* Alternative [[immunosuppression]]
|
* [[HELLP syndrome]]
* [[TTP]]
* [[Chronic lymphocytic leukemia|CLL]]
|-
|[[Sideroblastic anemia]]
|
* [[Alcoholism]]
* [[Lead poisoning]]
* [[Vitamin B6 deficiency]]
* [[Isoniazid]]
* [[Chloramphenicol]]
|
* [[Microcytic anemia|Microcytic]] (<80 femtoliter)
Or
* [[Normocytic anemia|Normocytic]] (80-100 femtoliter)
|
* Ringed sideroblasts in [[bone marrow]]
* Low [[vitamin B6]] level
* High [[lead]] level
|
* [[Pallor]]
* [[Muscle weakness|Weakness]]
|
* Removal of offending [[medication]]
* High-dose [[vitamin B6]] (up to 200mg daily)
* Avoidance of [[splenectomy]]
* Symptomatic [[Blood transfusion|transfusion]] support with [[iron]] [[chelation]] as needed
|
* [[Myelodysplastic syndrome]]
* [[Myeloproliferative neoplasm]]
* [[Iron overload]]
|-
|[[Anemia of chronic disease]]
|
* [[Chronic kidney disease]]
* [[Rheumatologic disease]]
* [[Cancer]]
* [[HIV]]
* Chronic infection; excess release of [[IL-1]] and [[IL-6]]
|
* [[Normocytic anemia|Normocytic]] (80-100 femtoliter)
|
* Elevated [[ESR]] and [[CRP]]
* Elevated [[hepcidin]]
* Low serum [[iron]]
* Low [[transferrin]]
* Elevated [[ferritin]]
|
* [[Pallor]]
* [[Weakness]]
|
* Treatment of the underlying cause; [[erythropoiesis]]-stimulating agents
* Supportive [[Red blood cell transfusion|red blood cell transfusions]]
|
* [[Inflammatory bowel disease]]
|-
|[[Thalassemia]]
|
* [[Genetic defect]] with alpha- or [[beta-globin]] production
|
* [[Microcytic]] (<80 femtoliter)
|
* Abnormal [[hemoglobin]] [[electrophoresis]] (in [[beta-thalassemia]])
|
* [[Irritability]]
* [[Growth retardation]]
* [[Jaundice]]
* [[Hepatomegaly]]
* [[Splenomegaly]]
|
* [[Blood transfusion|Transfusion]] support
* [[Iron]] chelation
* [[Gene therapy]] if available
|
* [[Extramedullary hematopoiesis]]
|-
|[[Iron deficiency anemia]]
|
* Loss of [[iron]] from [[gastrointestinal]] blood loss or [[menstrual]] [[blood loss]]
|
* [[Microcytic]] (<80 femtoliter)
|
* Low serum [[iron]]
* Elevated [[transferrin]]
* Low [[transferrin saturation]]
* Low [[ferritin]]
|
* [[Pallor]]
* [[Weakness]]
* Positive [[occult blood]] testing (if [[Gastrointestinal bleeding|GI bleeding]])
|
* Intravenous or oral iron supplementation
|
* [[Blood loss|Chronic blood loss]]
|-
|[[Erythropoietin]] deficiency
|
* [[Chronic kidney disease]] or other [[renal dysfunction]]
|
* [[Normocytic anemia|Normocytic]] (80-100 femtoliter)
|
* Low [[Erythropoietin|erythropoietin level]]
|
* [[Pallor]]
* [[Weakness]]
* Signs of [[chronic kidney disease]]
|
* [[Epoetin alfa]] 50-100 units/kg 3 times weekly
* Darbepoietin 0.45 mcg/kg weekly or 0.75 mcg/kg every 2 weeks<ref name="pmid28626220">{{cite journal| author=Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J et al.| title=A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. | journal=Leukemia | year= 2017 | volume= 31 | issue= 9 | pages= 1944-1950 | pmid=28626220 | doi=10.1038/leu.2017.192 | pmc=5596208 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28626220  }} </ref>
|
* [[Dialysis]] dependence
* [[Myelodysplastic syndrome]]
|-
|[[Vitamin B12 deficiency|Vitamin B12]] or [[folate deficiency]]
|
* [[Pernicious anemia]]
* [[Diphyllobothrium latum infection]]
* [[Nutritional deficiency]]
* [[Crohn's disease|Crohn's disease of terminal ileum]]
|
* [[Macrocytic anemia|Macrocytic]] (>100 femtoliter)
|
* Low vitamin B12 or folate level
* [[Megaloblastic anemia]] with  hypersegmented [[neutrophils]]
|
* [[Numbness]]
* [[Weakness]]
* [[Tingling]]
* [[Paresthesias]]
|
* [[Vitamin B12]] 1000mcg daily
* [[Folate]] 1mg daily
|
* [[Neuropathy]]
|}


==References==
==References==

Revision as of 04:57, 15 November 2017

Thalassemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thalassemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thalassemia differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thalassemia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thalassemia differential diagnosis

CDC on Thalassemia differential diagnosis

Thalassemia differential diagnosis in the news

Blogs on Thalassemia differential diagnosis

Directions to Hospitals Treating Thalassemia

Risk calculators and risk factors for Thalassemia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Differential Diagnosis

Characteristic/Parameter Etiology Mean corpuscular volume Laboratory abnormalities Physical examination Treatment Other associated abnormalities
Hemolytic anemia
Sideroblastic anemia

Or

Anemia of chronic disease
Thalassemia
Iron deficiency anemia
  • Intravenous or oral iron supplementation
Erythropoietin deficiency
  • Epoetin alfa 50-100 units/kg 3 times weekly
  • Darbepoietin 0.45 mcg/kg weekly or 0.75 mcg/kg every 2 weeks[1]
Vitamin B12 or folate deficiency


References

  1. Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J; et al. (2017). "A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes". Leukemia. 31 (9): 1944–1950. doi:10.1038/leu.2017.192. PMC 5596208. PMID 28626220.

Template:WH Template:WS